Levofloxacin
- Generic Name
- Levofloxacin
- Brand Names
- Levaquin, Quinsair
- Drug Type
- Small Molecule
- Chemical Formula
- C18H20FN3O4
- CAS Number
- 100986-85-4
- Unique Ingredient Identifier
- RIX4E89Y14
- Background
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic ofloxacin. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along w...
- Indication
In oral and intravenous formulations, levofloxacin is indicated in adults for the treatment of various infections caused by susceptible bacteria, including infections of the upper respiratory tract, lower respiratory tract, skin, skin structures, urinary tract, and prostate. The oral formulation is also indicated in both adults and children 6 months of age a...
- Associated Conditions
- Abscesses caused by susceptible bacteria, Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) caused by susceptible bacteria, Acute Pyelonephritis caused by Infection Due to Escherichia Coli, Bacterial Conjunctivitis caused by susceptible bacteria, Cellulitis caused by susceptible bacteria, Community Acquired Pneumonia (CAP) caused by susceptible bacteria, Furuncle caused by susceptible bacteria, Impetigo caused by susceptible bacteria, Inhalational Anthrax, Nosocomial Pneumonia caused by Pseudomonas Infections, Nosocomial Pneumonia caused by susceptible bacteria, Plague caused by Yersinia pestis, Pyoderma caused by susceptible bacteria, Wound Infections caused by susceptible bacteria, Acute bacterial sinusitis caused by susceptible bacteria, Chronic Bacterial prostatitis caused by susceptible bacteria, Chronic Pseudomonas Infections, Complicated Urinary Tract Infection caused by susceptible bacteria, Complicated skin and skin-structure infections caused by susceptible bacteria, Uncomplicated Urinary Tract Infection caused by susceptible bacteria, Uncomplicated skin and skin-structure infections caused by susceptible bacteria
- Associated Therapies
- -
Healthy Patients & Effect of Antibiotics
- Conditions
- Interventions
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2022-11-10
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 20
- Registration Number
- NCT03098485
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Antibiotics to Decrease Post ERCP Cholangitis
- First Posted Date
- 2017-03-22
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 200
- Registration Number
- NCT03087656
- Locations
- 🇺🇸
Los Angeles County Hospital, Los Angeles, California, United States
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
- Conditions
- Interventions
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2022-01-06
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 1205
- Registration Number
- NCT03032510
Phase 3 Multicenter Randomized Double Blind Placebo Controlled Study With Antibacterial Prophylaxis in Azacitidine Treated MDS Patients
- First Posted Date
- 2016-12-05
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 67
- Registration Number
- NCT02981615
- Locations
- 🇮🇱
Chim Sheba Medical Center, Tel Hashomer, Israel
Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin
- Conditions
- Interventions
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Boston University
- Registration Number
- NCT02975570
Tailored Versus Empiric Therapy for Helicobacter Pylori Treatment
- Conditions
- Interventions
- First Posted Date
- 2016-10-17
- Last Posted Date
- 2018-08-15
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 382
- Registration Number
- NCT02935010
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai, Shanghai, China
🇨🇳Zhongshan Hospital,Fudan University, Shanghai, Shanghai, China
🇨🇳Shanghai Tenth People's Hospital, Tongji University, Shanghai, Shanghai, China
Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2016-09-15
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 3900
- Registration Number
- NCT02901288
- Locations
- 🇨🇳
The Infectious Hospital of Hebi, Hebi, Henan, China
🇨🇳Wuhan Institute For Tuberculosis Control, Wuhan, Hubei, China
🇨🇳Anhui Chest Hospital, Hefei, Anhui, China
Levofloxacin-Doxycycline for Helicobacter Pylori Eradication in Saudi Arabia
- Conditions
- Interventions
- First Posted Date
- 2016-08-31
- Last Posted Date
- 2016-08-31
- Target Recruit Count
- 55
- Registration Number
- NCT02884713
The Preventive Infection Role of One Week Antibiotics Before Minimally Invasive Upper Tract Lithotomy
- Conditions
- Interventions
- First Posted Date
- 2016-06-03
- Last Posted Date
- 2019-10-01
- Target Recruit Count
- 150
- Registration Number
- NCT02789579
- Locations
- 🇨🇳
Department of Pharmacy, Xinhua Hospital, Shanghai Jiaotong University School of Medicine.Kongjiang Road 1665,, Shanghai, Shanghai, China
Efficiency Study of Aspirin to Prevent the Occurrence of Prostate Cancer
- First Posted Date
- 2016-05-02
- Last Posted Date
- 2016-05-02
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT02757365
- Locations
- 🇨🇳
West Hospital of China, Chengdu, Sichuan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.